Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company�s programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act through mechanisms and targets to kill cancer and protect healthy cells. The Company�s lead product candidates include Entolimod, which is designed for biodefense indication and as an oncology drug, and Curaxin CBL0137, a lead oncology product candidate. The Company�s products include Entolimod (CBLB502) Biodefense, Entolimod (CBLB502) Oncology, CBLB612, CBLC102 and CBLC137, Revercom, Mobilan, Arkil, Antimycon and Xenomycins. The Company�s subsidiaries include Incuron, LLC, which develops product candidates CBL0102 and CBL0137 for oncology indications; and Panacela, which develops new preclinical product candidates, primarily focused in oncology.